71 – 80 of 554
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App NL−F/NL−F knock-in mouse model of Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals
(
- Contribution to journal › Article
-
Mark
European consensus for the diagnosis of MCI and mild dementia : Preparatory phase
(
- Contribution to journal › Article
-
Mark
Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab
(
- Contribution to journal › Article
-
Mark
Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy
(
- Contribution to journal › Article
-
Mark
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
(
- Contribution to journal › Article
-
Mark
Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease
2023) In Annals of Neurology(
- Contribution to journal › Article
-
Mark
Harnessing cognitive trajectory clusterings to examine subclinical decline risk factors
(
- Contribution to journal › Article
-
Mark
Gray matter hypoperfusion is a late pathological event in the course of Alzheimer's disease
2023) In Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 43(4). p.565-580(
- Contribution to journal › Article